Steatorrhea classification

Jump to navigation Jump to search

Steatorrhea Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Steatorrhea from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Steatorrhea classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Steatorrhea classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Steatorrhea classification

CDC on Steatorrhea classification

Steatorrhea classification in the news

Blogs on Steatorrhea classification

Directions to Hospitals Treating Steatorrhea

Risk calculators and risk factors for Steatorrhea classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2] Sunny Kumar MD [3]

Overview

Steatorrhea may be classified based on etiology into 3 types, intestinal, biliary, and pancreatic steatorrhea.

Classification

Steatorrhea may be classified based on etiology into 3 types, intestinal, biliary, and pancreatic steatorrhea.[1][2][3][4]

References

  1. Kumar R, Bhargava A, Jaiswal G (2017). "A case report on total pancreatic lipomatosis: An unusual entity". Int J Health Sci (Qassim). 11 (4): 71–73. PMC 5654180. PMID 29085272.
  2. Previti E, Salinari S, Bertuzzi A, Capristo E, Bornstein S, Mingrone G (2017). "Glycemic control after metabolic surgery: a Granger causality and graph analysis". Am J Physiol Endocrinol Metab. 313 (5): E622–E630. doi:10.1152/ajpendo.00042.2017. PMID 28698280.
  3. Vakhrushev YM, Lukashevich AP (2017). "[Specific features of impaired intestinal digestion, absorption, and microbiocenosis in patients with cholelithiasis]". Ter Arkh. 89 (2): 28–32. doi:10.17116/terarkh201789228-32. PMID 28281512.
  4. Scarpignato C, Gatta L, Zullo A, Blandizzi C, SIF-AIGO-FIMMG Group. Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners (2016). "Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression". BMC Med. 14 (1): 179. doi:10.1186/s12916-016-0718-z. PMC 5101793. PMID 27825371.

Template:WS Template:WH